Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox Mechanism in Chronic Migraine
NCT03381261Phase 4Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Dec 2017
- Primary completion
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of botulinum toxin type A in chronic migraine, sponsored by Massachusetts General Hospital. Primary endpoint: Inflammatory Gene Expression in Chronic Migraine Patients With OnabotulinumtoxinA Injection Treatment Versus No Treatment at 1 year. Started Dec 2017; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
chronic migraine
Beyond the preview
Go deeper on NCT03381261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03381261.